InsidersTradesSigma
Total declarations
Companies
▲ Purchases (47 ops.)
▼ Sales (83 ops.)
Insider track record
Board DirectorDisclosed buys
47
Disclosed sells
83
T+90 hit rate
47%
T+90 mean return
-12.8%
Across 19 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by ORBIMED ADVISORS LLC, Board Member. Director active across 40 companies, notably SpringWorks Therapeutics, Inc.. Cumulatively, 162 reports have been recorded. Breakdown: 47 buys · 83 sells. Total volume traded: €336.3m. History available since 7 June 2021. The latest transaction was filed on 14 May 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations162 total
24,846 sharesCommon StockSEC:0000947871-26-000653:0
1,477 sharesCommon StockSEC:0000947871-26-000653:1
46,776 sharesCommon StockSEC:0000947871-26-000653:3
787,024 sharesCommon StockSEC:0000947871-26-000653:2
134,136 shares@ US$15.8321.4% of flowCommon StockSEC:0000947871-25-000548:0
78,049 shares@ US$0.340.4% of flowCommon StockSEC:0000947871-25-000423:0
10,326 shares@ US$0.380.1% of flowCommon StockSEC:0000947871-25-000415:0
56,004,974 shares@ US$0.42100.0% of flowCommon StockSEC:0000947871-25-000392:0
3,571,428 shares@ US$1.5929.9% of flowCommon StockSEC:0000947871-25-000384:0
372,578 shares@ US$20.1339.2% of flowCommon StockSEC:0000947871-25-000359:0
Ideal exit: 29 Dec 2025 (T+270)
1,956 shares@ US$54.110.5% of flowCommon StockSEC:0000947871-25-000345:0
13,517 shares@ US$54.023.5% of flowCommon StockSEC:0000947871-25-000333:0
68,766 shares@ US$54.2917.9% of flowCommon StockSEC:0000947871-25-000308:0
17,962 shares@ US$9.90100.0% of flowCommon StockSEC:0000947871-25-000199:0
Ideal exit: 11 Nov 2025 (T+270)
3,154,959 sharesCommon StockSEC:0000947871-25-000120:0
126,209 shares@ US$0.661.5% of flowCommon StockSEC:0000947871-25-000034:0
19,481 shares@ US$0.770.3% of flowCommon StockSEC:0000947871-25-000021:0
230,321 shares@ US$0.602.5% of flowCommon StockSEC:0000947871-24-001037:0
54,181 shares@ US$0.840.8% of flowCommon StockSEC:0000947871-24-000998:0
76,200 shares@ US$0.791.1% of flowCommon StockSEC:0000947871-24-000995:0
323,916 shares@ US$3.20100.0% of flowCommon StockSEC:0001213900-24-094666:0
721,956 sharesCommon StockSEC:0000947871-24-000806:0
39,300 shares@ US$0.710.5% of flowCommon StockSEC:0000947871-24-000769:0
63,100 shares@ US$0.740.8% of flowCommon StockSEC:0000947871-24-000763:0
2,658,428 sharesCommon StockSEC:0000950170-24-107538:0
25 of 162 declarations
About ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC is a life-sciences-focused investment firm with a strong footprint in the governance of U.S.-listed biotechnology companies. Across the affiliated companies you listed—89bio, Janux Therapeutics, Corvus Pharmaceuticals, Adicet Bio, and Repare Therapeutics—OrbiMed typically participates through its investment professionals and board representatives rather than through a single operating executive. Public-company filings show OrbiMed partners serving in director roles at multiple portfolio companies, including Peter A. Thompson, M.D. at Janux Therapeutics and Corvus Pharmaceuticals, and Carl L. Gordon, Ph.D. at Adicet Bio, where he serves as board chair. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710072/000155837024005905/tmb-20240607xdef14a.htm)) For SEO and corporate-governance purposes, the most notable current or recent role to associate with OrbiMed Advisors LLC is therefore Board Member, or more precisely an institutional investor representative on the boards of portfolio companies. In that capacity, OrbiMed is known for supporting governance, financing, and strategic oversight for development-stage and commercial-stage healthcare businesses. The company’s representatives bring deep experience in biotechnology investing, molecular biology, drug development, and healthcare private equity, and that expertise is frequently cited in public filings as a qualification for board service. This makes OrbiMed a meaningful governance stakeholder in public biotech markets, particularly on the NASDAQ and NYSE. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710072/000155837024005905/tmb-20240607xdef14a.htm)) OrbiMed’s broader profile is that of a global healthcare investment manager with more than 20 years of experience investing across biopharmaceuticals, medical devices, diagnostics, and healthcare services. Its board-level influence is typically exercised through experienced partners who help guide capital allocation, clinical-development priorities, portfolio strategy, and value-creation decisions. Public disclosures show that its affiliated directors have served on numerous boards and have often been involved in companies pursuing major strategic milestones, including financing rounds, pipeline progression, and other board-approved corporate actions. In short, OrbiMed Advisors LLC is best characterized as an influential healthcare investor and governance participant rather than an operating company executive, with a particularly notable presence in U.S. public biotech governance. ([orbimed.com](https://www.orbimed.com/about/?utm_source=openai))
